Early and Sustained Treatment Satisfaction Observed in Patients With Moderate to Severe Psoriasis Treated With Ixekizumab: Results From Second Interim Analysis of the Real-World Psoriasis in Special Areas (PSoSA) Study. J of Skin 2025, 9 (1), s509. https://doi.org/10.25251/skin.9.supp.509.